PMC6088479_01
Case 1: changes in myocardial perfusion before and after homeopathic therapy with cardiologist's opinion (via email): (a) 4 December 2011, (b) 6 December 2017 and (c) cardiologist's opinion.
10.1177_2050313X18792813-fig1.jpg
PMC6088479_01_10.1177_2050313X18792813-fig1.jpg
fig1-2050313X18792813
Laboratory investigations: myocardial perfusion single-photon emission computed tomography (SPECT) 13 April 2011 (Figure 1(a)).
PMC6088479_02
Case 2: changes in rhythm and ECG before and after homeopathic therapy: (a) 23 June 2015, (b) 26 June 2015 and (c) 10 April 2017.
10.1177_2050313X18792813-fig2.jpg
PMC6088479_02_10.1177_2050313X18792813-fig2.jpg
fig2-2050313X18792813
Laboratory investigations and follow-up: electrocardiograph (ECG; 23 June 2015) (Figure 2(a)) showed ST segment elevation, in I, aVL and V1-V5 with reciprocal changes in the inferior leads; anterior wall infarction. Arnica montana 30C. A few minutes later, the cardiac monitor showed a sinus rhythm, confirmed by the ECG on 26 June 2017(Figure 2(b)). The echocardiography (Figure 2(c)) shows a stable cardiac state, despite remodelling of myocardium and reduced left ventricular function.
PMC6088479_03
Case 3: changes in the cardiac status and ejection fraction before and after homeopathic therapy: (a) 27 November 2016, (b) 27 December 2016, (c) 7 February 2017, (d) 13 October 2017 and (e) 12 April 2018.
10.1177_2050313X18792813-fig3.jpg
PMC6088479_03_10.1177_2050313X18792813-fig3.jpg
fig3-2050313X18792813
Laboratory investigations: echocardiography (27 November 2016) (Figure 3(a)): dilated left atrium; dilated left ventricle; severe hypokinesia of entire septum, apex and anterior wall; mild to moderate MR; sclerosed aortic valve; mild tricuspid regurgitation; ejection fraction 24%. Echocardiography was repeated on 27 December 2016 (Figure 3(b)) and found the same findings as above, but the ejection fraction had reduced to 16%. Homeopathic intervention: homeopathic therapy was begun on 29 December 2016; one dose of Calcarea phosphorica 200C was given with evidence of improvement in the ejection fraction (Figure 3(c)). Most recent laboratory investigation (12 April 2018) (Figure 3(e)): dilated left atrium; mild concentric left ventricular hypertrophy; mild regional wall motion abnormalities in inferoseptal and inferior segments with preserved thickness; fair LV systolic function; grade 1 diastolic dysfunction; normal valves morphology; mild MR; trivial tricuspid regurgitation; ejection fraction 64.68%.